Overview

A Study of BL-M07D1 in Patients With HER2-expressing Recurrent or Metastatic Gynecologic Malignancies

Status:
Recruiting

Trial end date:
2025-12-01

Target enrollment:

Participant gender:

Summary

This study is a single-arm, open, multicenter, non-randomized phase Ib/II clinical study evaluating the efficacy and safety of BL-M07D1 for injection in patients with HER2-expressing recurrent or metastatic gynecologic malignancies.

Phase:

Phase 1/Phase 2

Details

Lead Sponsor:

Sichuan Baili Pharmaceutical Co., Ltd.

Collaborator:

Baili-Bio (Chengdu) Pharmaceutical Co., Ltd.